

Improving the Stability of a Moisture-Sensitive Drug - Ranitidine HCl

CHALLENGE

Multi-compartment compliance aids (MCA) or pill organizers are frequently used by patients to manage their treatment regimes. However, there are not many studies showing how the stability of drugs when stored in these aids is impacted. The purpose of this study was to evaluate how the selection of excipients, such as Starch 1500[®], partially pregelatinized starch, can impact the formulation of moisture sensitive drugs when used in a MCA. Ranitidine HCl was used as the model drug.



Multi-compartment compliance aid (MCA)

METHODS










- Two formulations of ranitidine HCl, with and without Starch 1500, were film coated, then together with a film coated marketed product all were dispensed into a MCA for stability studies at 40°C/75% RH.

Composition of Ranitidine HCl 150 mg tablets

| Ingredients | Formula A % | Formula B % |
|----------------------------|----------------|----------------|
| Ranitidine HCl | 54.00 | 54.00 |
| Starch 1500 | 15.08 | --- |
| Microcrystalline cellulose | 30.17 | 45.25 |
| Colloidal silicone dioxide | 0.50 | 0.50 |
| Magnesium stearate | 0.25 | 0.25 |
| Total | 100.00 | 100.00 |

RESULTS


Visual observation following stability in MCA

| | Formulation A with Starch 1500 | Formulation B with MCC | Reference Marketed Product |
|--------|---|---|---|
| Day 1 |  |  |  |
| Day 7 |  |  |  |
| Day 14 |  |  |  |

Formulation A, containing Starch 1500, performed better than Formulation B with MCC alone and the reference marketed product formulation.

Assay and Impurity Analysis

The level of total impurities in the formulation with Starch 1500 was significantly lower (12% w/w) compared to other formulations.



CONCLUSION

- Inclusion of Starch 1500 in the core formulation significantly reduced the rate of ranitidine degradation
- The stability improvement of the drug is due to moisture scavenging property of Starch 1500 in the formulation, which reduces drug hydrolysis and degradation

The information contained herein, to the best of Colorcon, Inc.'s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages.

Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer's application.

For more information, contact your Colorcon representative or call:

North America +1-215-699-7733 Europe/Middle East/Africa +44-(0)-1322-293000 Latin America +54-1-5556-7700 India +91-832-6727373 China +86-21-61982300

You can also visit our website at www.colorcon.com



© BPSI Holdings LLC, 2020.

The information contained in this document is proprietary to Colorcon and may not be used or disseminated inappropriately.

All trademarks, except where noted, are property of BPSI Holdings, LLC.

Tech Bulletin_Ranitidine_Starch1500_v1_072020